Enables higher process efficiency, which increases viral filtration throughput with lower costs and faster processing
The new Viresolve Pro Shield H virus filter from Merck removes protein aggregates and impurities that foul virus filters in high pH and high conductivity monoclonal antibody (mAb) feed streams.
It is used as a prefilter with the firm's Viresolve Pro Device for more robust, cost-effective viral clearance.
When the two products are used together, the Viresolve Pro Shield H significantly increases processing capacity, while preserving high virus removal and high flux, the firm said.
The result is an efficient virus filtration process with lower filter costs, faster processing times and less sensitivity to feed stream variability.
'As feed stream characteristics continue to change, filtration products must evolve to enable successful viral clearance to ensure drug safety,' said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation at Merck's life science business.
'Viresolve Pro Shield H effectively improves aggregate removal and reduces the required virus filtration area needed to process feed streams, while delivering the same high level of virus clearance our customers rely on.'
Recombinant protein, mAb, fusion protein and antibody fragment feed streams can be challenging to process efficiently, both in terms of time and cost, because these proteins tend to aggregate during production.
Aggregates can cause virus filters to foul more rapidly, reducing the amount of feed that can be processed and increasing the number of filters required to process the same volume.